How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

12,384 results for

Prostate Radiotherapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline Guideline Endorsement 3-22 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline H. Lukka, J. Brown, C. Catton, B. Shayegan (...) and the Hypofractionated Radiation Therapy for Prostate Cancer Guideline Development Group Report Date: April 28, 2020 This publication is an OH (CCO) Hypofractionated Radiation Therapy for Prostate Guideline Development Group Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO and AUA Evidence-based Guideline. The original publication is available at: https://www.astro.org/Patient-Care-and-Research/Clinical-Practice-Statements/ASTRO-39;s- guideline

2020 Cancer Care Ontario

2. Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines

Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Last updated: September 5, 2019 Project Number (...) : RA1061-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of radical prostatectomy for early-stage or screen-detected prostate cancer? What is the clinical effectiveness of radiation therapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of radical prostatectomy for prostate cancer? What are the evidence-based guidelines on the use of radiation therapy

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Randomised controlled trial: Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10?years of follow-up Full Text available with Trip Pro

Randomised controlled trial: Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10?years of follow-up Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you (...) prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up Article Text Therapeutics/Prevention Randomised controlled trial Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up Philipp Dahm 1 , 2 , Dragan Ilic 3 , Timothy Wilt 4 , 5 Statistics from Altmetric.com Commentary

2017 Evidence-Based Medicine

5. Hypofractionated Radiation Therapy for Localized Prostate Cancer

Hypofractionated Radiation Therapy for Localized Prostate Cancer Prostate Cancer: Hypofractionated Radiotherapy Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology (...) that is similar to EBRT delivered using conventional fractionation (180 to 200 cGy per day) ( ). 23-33 The largest multicenter trials are the Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer (CHHiP) trial, Prostate Fractionated Irradiation Trial (PROFIT), Radiation Therapy Oncology Group (RTOG) 0415 trial, and the Dutch Hypofractionated versus Conventionally Fractionated Radiotherapy for Patients with Prostate Cancer (HYPRO) trial. 23,26-28 The CHHiP trial

2018 American Urological Association

6. Hypofractionated Radiation Therapy for Localized Prostate Cancer Full Text available with Trip Pro

Hypofractionated Radiation Therapy for Localized Prostate Cancer Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.18.01097 Journal of Clinical Oncology - published online before print October 11, 2018 Hypofractionated Radiation Therapy (...) for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline x Scott C. Morgan , x Karen Hoffman , x D. Andrew Loblaw , x Mark K. Buyyounouski , x Caroline Patton , x Daniel Barocas , x Soren Bentzen , x Michael Chang , x Jason Efstathiou , x Patrick Greany , x Per Halvorsen , x Bridget F. Koontz , x Colleen Lawton , x C. Marc Leyrer , x Daniel Lin , x Michael Ray , and x Howard Sandler Scott C. Morgan, The Ottawa Hospital and University of Ottawa, Ottawa; D. Andrew Loblaw, Odette Cancer

2018 American Society of Clinical Oncology Guidelines

7. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer

in this health technology assessment includes treatment-naïve men with stage I-II localized prostate cancer who undergo definitive monotherapy with CyberKnife SBRT. Clinical Alternatives: Prostate cancer treatment is guided by the initial disease risk category. Options include active surveillance or watchful waiting, radical prostatectomy, external beam radiation therapy using 3-dimensional conformal radiotherapy or intensity-modulated radiotherapy; high-dose-rate brachytherapy; high-intensity-focused (...) Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) monotherapy of primary localized prostate cancer HAYES, Inc Record Status This is a bibliographic record

2017 Health Technology Assessment (HTA) Database.

8. Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer

CyberKnife SBRT boost. Clinical Alternatives: Prostate cancer treatment is guided by the initial disease risk category. Options can include active surveillance or watchful waiting; radical prostatectomy; EBRT using 3-dimensional conformal radiation therapy or intensitymodulated radiotherapy; HDR brachytherapy; high-intensity-focused ultrasound; hormonal therapy; cryosurgery; or combinations thereof. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD (...) Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer Stereotactic body radiation therapy with CyberKnife Robotic Radiosurgery System (Accuray Inc.) boost treatment in primary localized prostate cancer HAYES, Inc Record Status This is a bibliographic record

2017 Health Technology Assessment (HTA) Database.

9. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. (Abstract)

Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. Understanding adverse effects of contemporary treatment approaches for men with favorable-risk and unfavorable-risk localized prostate cancer could inform treatment selection.To compare functional outcomes associated with prostate cancer treatments over 5 years after treatment.Prospective, population (...) ), nerve-sparing prostatectomy (n = 675), external beam radiation therapy (EBRT; n = 261), or low-dose-rate brachytherapy (n = 87) for men with favorable-risk disease and treatment with prostatectomy (n = 402) or EBRT with androgen deprivation therapy (n = 217) for men with unfavorable-risk disease.Patient-reported function, based on the 26-item Expanded Prostate Index Composite (range, 0-100), 5 years after treatment. Regression models were adjusted for baseline function and patient and tumor

2020 JAMA

10. Re: Surrogate End Points for All-Cause Mortality in Men with Localized Unfavorable-Risk Prostate Cancer Treated with Radiation Therapy vs Radiation Therapy plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial. (Abstract)

Re: Surrogate End Points for All-Cause Mortality in Men with Localized Unfavorable-Risk Prostate Cancer Treated with Radiation Therapy vs Radiation Therapy plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial. 29310183 2019 01 21 2019 01 21 1527-3792 199 1 2018 01 The Journal of urology J. Urol. Re: Surrogate End Points for All-Cause Mortality in Men with Localized Unfavorable-Risk Prostate Cancer Treated with Radiation Therapy vs Radiation Therapy plus (...) Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial. 28 S0022-5347(17)77695-1 10.1016/j.juro.2017.10.008 Taneja Samir S SS eng Journal Article Comment 2017 10 06 United States J Urol 0376374 0022-5347 0 Biomarkers AIM IM JAMA Oncol. 2017 May 1;3(5):652-658 28097317 Biomarkers Humans Male Prostatic Neoplasms 2018 1 10 6 0 2018 1 10 6 0 2019 1 22 6 0 ppublish 29310183 S0022-5347(17)77695-1 10.1016/j.juro.2017.10.008

2019 The Journal of urology Controlled trial quality: uncertain

11. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer

with training in, and experience of, transperineal interventional procedures. 2 2 Indications and current treatments Indications and current treatments 2.1 Current treatment options for localised or locally advanced prostate cancer include 'watchful waiting' , active surveillance, radiotherapy, radical prostatectomy, cryotherapy, high-intensity focused ultrasound, androgen deprivation therapy and chemotherapy (as recommended in NICE's guideline on prostate cancer: diagnosis and treatment). 2.2 Radiation (...) therapy is an established curative treatment and can be either external-beam radiotherapy or brachytherapy (also called interstitial radiotherapy). Brachytherapy can be given at either low- or high-dose rates. Low-dose-rate brachytherapy may be used alone or in combination with external-beam radiotherapy. 3 3 The procedure The procedure 3.1 Radiotherapy for prostate cancer can cause rectal damage because of the close proximity of the prostate to the rectum. Symptoms include diarrhoea, incontinence

2017 National Institute for Health and Clinical Excellence - Interventional Procedures

12. Biodegradable Rectal Spacers for Prostate Cancer Radiotherapy

beam radiotherapy in terms of rectal sparing and volume consistency. Radiother Oncol. 2015;116(2):221-5. 19. Strom TJ, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC, et al. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy intensity modulated radiation therapy. Radiother Oncol. 2014;111(1):126-31. 20. Pinkawa M, Berneking V, Schlenter M, Krenkel B, Eble MJ. Quality of Life after Radiation Therapy for Prostate Cancer (...) trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92(5):971-7. 2. Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97(5):976-85. 3. Pinkawa M, Berneking V, Konig L, Frank D, Bretgeld M, Eble MJ. Hydrogel

2019 Cancer Care Ontario

13. Salvage Stereotactic Body Radiation Therapy for Local Prostate Cancer Recurrence After Radiation Therapy: A Retrospective Multicenter Study of the GETUG. Full Text available with Trip Pro

Salvage Stereotactic Body Radiation Therapy for Local Prostate Cancer Recurrence After Radiation Therapy: A Retrospective Multicenter Study of the GETUG. To assess the efficacy and safety of salvage stereotactic body radiation therapy (SBRT) in patients with biopsy-proven local prostate cancer recurrence after radiation therapy.Between April 2010 and January 2017, 100 patients were included in 7 centers. Disease extension was assessed by pelvic multiparametric magnetic resonance imaging (...) and choline positron emission tomography in 87% and 94% of patients, respectively. The median time interval between the 2 treatments was 7.5 years (range, 2-18). Median prostate-specific antigen at recurrence was 4.3 ng/mL (range, 2-38). Median SBRT dose was 36 Gy (range, 25-36.25) in 6 fractions (range, 5-6), every other day. Thirty-four percent of patients were treated by androgen deprivation therapy for a median duration of 12 months. Toxicity was assessed according to Common Terminology Criteria

2019 Biology and Physics

14. Combined external beam radiation therapy and brachytherapy versus radical prostatectomy with adjuvant radiation therapy for Gleason 9-10 prostate cancer. (Abstract)

Combined external beam radiation therapy and brachytherapy versus radical prostatectomy with adjuvant radiation therapy for Gleason 9-10 prostate cancer. It remains controversial whether external beam radiation therapy (EBRT) with brachytherapy boost (BT) provides equivalent oncologic outcomes compared with radical prostatectomy (RP) with or without adjuvant radiation therapy (ART) for men with Gleason 9-10 prostate cancer. We sought to compare ComboRT (EBRT+BT) to RP+ART for Gleason 9-10 (...) the SEER cohort, there was no difference in 5-year PCSM (6.0% vs 5.7%, AHR 1.22, 95% CI 0.0.88-1.71, p=0.234). There was no significant interaction between age (>=65 versus <65 years) and treatment modality for the NCDB or SEER cohorts.For patients with Gleason 9-10 prostate cancer, multi-modality surgical therapy is equivalent to ComboRT.

2019 Journal of Urology

15. Clinical Appropriateness Guidelines: Radiation Oncology Brachytherapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatment guidelines

, Chan LW, Park-Somers E, Roach M 3rd. Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT. Int J Radiat Oncol Biol Phys. 2009;73(1):53-60. 7. Cosma D, Barnett E, Le K, et al. Introduction of moderate deep inspiration breath hold for radiation therapy of the left breast: Initial experience of a regional cancer center. Practical Radiat Oncol. 2014;4(5):298-305. 8. Dawson LA, Jaffray DA. Advances in image-guided (...) radiation therapy. J Clin Oncol. 2007;25(8):938-946. 9. Dearnaley D, Griffen C, Syndikus I, et al. Image guided radiotherapy (IGRT) for prostate cancer - results from the CHHiP IGRT phase II sub-study (CRUK/06/016). Poster presented at: 2014 NCRI Cancer Conference; November 2-5, 2004; Liverpool, UK. Abstract no. B298. 10. Eldredge HB, Studenski M, Keith SW, et al. Post-prostatectomy image-guided radiation therapy: evaluation of toxicity and inter-fraction variation using online cone-beam CT. J Med

2018 AIM Specialty Health

16. Salvage reirradiation for local failure of prostate cancer after curative radiation therapy: Association of rectal toxicity with dose distribution and normal-tissue complication probability models Full Text available with Trip Pro

Salvage reirradiation for local failure of prostate cancer after curative radiation therapy: Association of rectal toxicity with dose distribution and normal-tissue complication probability models This study aimed to assess the impact of radiation dose on rectal toxicity after salvage external beam radiation therapy (EBRT) with or without a brachytherapy boost for exclusive local failures after the primary EBRT for prostate cancer.Fourteen patients with no severe residual late toxicity after (...) toxicity (grade ≤2).The 5-year grade ≥3 GI toxicity-free survival rate was 57.1%. The median rectal V70Gy and maximum dose to 1 cm3 (D1ccrect) at primary EBRT were both predictive for grade ≥3 GI toxicity (9% vs 0%; P = .04 and 72.2 Gy vs 66.8 Gy; P < .01, respectively). When adding primary radiation therapy (RT) and reirradiation plans, the median D1ccrect was 139.8 Gy versus 126.7 Gy (P < .01) for high and low GI toxicity groups. NTCP >10% at primary RT was predictive for high GI toxicity

2018 Advances in radiation oncology

17. Letter to the editor in response to Hopper et al, “Salvage image guided radiation therapy to the prostate after cryotherapy failure” Full Text available with Trip Pro

Letter to the editor in response to Hopper et al, “Salvage image guided radiation therapy to the prostate after cryotherapy failure” 30197945 2018 11 14 2452-1094 3 3 2018 Jul-Sep Advances in radiation oncology Adv Radiat Oncol Letter to the editor in response to Hopper et al, "Salvage image guided radiation therapy to the prostate after cryotherapy failure". 469 10.1016/j.adro.2018.02.002 Holtzman Adam A Department of Radiation Oncology, University of Florida College of Medicine (...) , Gainesville and Jacksonville, Florida. Hoppe Bradford S BS Department of Radiation Oncology, University of Florida College of Medicine, Gainesville and Jacksonville, Florida. eng Journal Article 2018 02 09 United States Adv Radiat Oncol 101677247 2452-1094 2018 01 31 2018 02 02 2018 02 03 2018 9 11 6 0 2018 9 11 6 0 2018 9 11 6 1 epublish 30197945 10.1016/j.adro.2018.02.002 S2452-1094(18)30027-7 PMC6127876 Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):465-71 26883560 Int J Radiat Oncol Biol Phys. 2012

2018 Advances in radiation oncology

18. Daily online image-guided radiotherapy for people undergoing radical prostate cancer treatment

Daily online image-guided radiotherapy for people undergoing radical prostate cancer treatment Daily online image-guided radiotherapy (prostate cancer) - Health Technology Wales > Daily online image-guided radiotherapy (prostate cancer) Daily online image-guided radiotherapy (prostate cancer) Topic Status Complete Daily online image-guided radiotherapy for people undergoing radical prostate cancer treatment. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale (...) University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER038 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend

2019 Health Technology Wales

19. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. (Abstract)

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localised prostate cancer. We aimed to investigate whether novel imaging using prostate-specific membrane antigen (PSMA) PET-CT might improve accuracy and affect management.In this multicentre, two-arm (...) , randomised study, we recruited men with biopsy-proven prostate cancer and high-risk features at ten hospitals in Australia. Patients were randomly assigned to conventional imaging with CT and bone scanning or gallium-68 PSMA-11 PET-CT. First-line imaging was done within 21 days following randomisation. Patients crossed over unless three or more distant metastases were identified. The primary outcome was accuracy of first-line imaging for identifying either pelvic nodal or distant-metastatic disease

2020 Lancet

20. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Tria (Abstract)

in mPCa, but to date, no randomised-controlled-trials (RCTs) have been published addressing this issue.To determine whether overall survival is prolonged by adding local treatment of the primary prostatic tumour with external beam radiation therapy (EBRT) to ADT.The HORRAD trial is a multicentre RCT recruiting 432 patients with prostate-specific antigen (PSA) >20ng/ml and primary bone mPCa on bone scan between 2004 and 2014.Patients were randomised to either ADT with EBRT (radiotherapy group) or ADT (...) benefit. Further research is needed to confirm our findings.This study investigated the effect of adding radiation therapy to the prostate to hormonal therapy in prostate cancer patients with metastasis to the bone at diagnosis. In our patient group, additional radiotherapy did not improve overall survival. Further research is needed to confirm our findings.Adding radiotherapy to the prostate in patients with bone metastatic prostate cancer does not improve overall survival.Copyright © 2018 European

2018 European Urology Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>